跳轉至內容
Merck
  • Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.

Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.

Cancer cell (2013-11-16)
Esther Castellano, Clare Sheridan, May Zaw Thin, Emma Nye, Bradley Spencer-Dene, Markus E Diefenbacher, Christopher Moore, Madhu S Kumar, Miguel M Murillo, Eva Grönroos, Francois Lassailly, Gordon Stamp, Julian Downward
摘要

RAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of the p110α subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is unknown whether interaction of RAS with PI3-kinase is required in established tumors. The need for RAS interaction with p110α in the maintenance of mutant Kras-driven lung tumors was explored using an inducible mouse model. In established tumors, removal of the ability of p110α to interact with RAS causes long-term tumor stasis and partial regression. This is a tumor cell-autonomous effect, which is improved significantly by combination with MEK inhibition. Total removal of p110α expression or activity has comparable effects, albeit with greater toxicities.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
泰莫西芬, ≥99%
Sigma-Aldrich
他莫昔芬 柠檬酸盐, ≥99%
他莫昔芬 柠檬酸盐, European Pharmacopoeia (EP) Reference Standard
他莫昔芬 柠檬酸盐, European Pharmacopoeia (EP) Reference Standard